References
- Shepherd L, Borges Á, Ledergerber B, et al. Infection-related and -unrelated malignancies, HIV and the aging population. HIV Med. 2016;17(8):590–600.
- Gopal S, Fedoriw Y, Kaimila B, et al. CHOP chemotherapy for aggressive non-Hodgkin lymphoma with and without HIV in the antiretroviral therapy era in Malawi. PLoS One. 2016;11(3):e0150445.
- Expert Consensus on Diagnosis and Treatment of AIDS-related Lymphoma. Chinese Society of Infectious Diseases, Chinese Society of Tropical Diseases and Parasitology, AIDS Section. Chin J AIDS STD. 2017;23(8):678–682.
- Wong AY, Marcotte S, Laroche M, et al. Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study. Antivir Ther. 2013;18(5):699–707.
- Barta SK, Lee JY, Kaplan LD, et al. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012;118(16):3977–3983.
- Barta SK, Samuel MS, Xue X, et al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol. 2015;26(5):958–966.
- Han X, Jemal A, Hulland E, et al. HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy. Cancer Epidemiol Biomarkers Prev. 2017;26(3):303–311.
- Besson C, Lancar R, Prevot S, et al. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. AIDS. 2017;31(18):2493–2501.
- Coutinho R, Pria AD, Gandhi S, et al. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS. 2014;28(5):689–697.